Louisiana State Employees Retirement System Purchases New Position in Ralliant Corporation $RAL

Louisiana State Employees Retirement System purchased a new stake in shares of Ralliant Corporation (NYSE:RAL) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 50,000 shares of the company’s stock, valued at approximately $2,080,000.

A number of other large investors have also recently made changes to their positions in RAL. Danske Bank A S purchased a new position in shares of Ralliant during the fourth quarter valued at approximately $25,000. V Square Quantitative Management LLC purchased a new stake in Ralliant in the fourth quarter worth $26,000. Allworth Financial LP boosted its holdings in Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after acquiring an additional 293 shares in the last quarter. Palisade Asset Management LLC bought a new stake in Ralliant in the third quarter valued at $26,000. Finally, BOKF NA purchased a new position in Ralliant during the 3rd quarter valued at $29,000.

Ralliant Stock Performance

Shares of RAL stock opened at $73.72 on Wednesday. Ralliant Corporation has a 12 month low of $37.27 and a 12 month high of $75.41. The stock has a market cap of $8.25 billion and a PE ratio of -6.74. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. The company’s fifty day moving average price is $59.20 and its 200-day moving average price is $51.56.

Ralliant (NYSE:RAL) last released its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The firm had revenue of $534.60 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The firm’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, equities analysts expect that Ralliant Corporation will post 2.64 EPS for the current fiscal year.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is currently -1.83%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on RAL shares. Citigroup upped their price objective on shares of Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. TD Cowen boosted their price target on shares of Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 20th. Evercore assumed coverage on shares of Ralliant in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price target for the company. Vertical Research lowered shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a report on Wednesday, May 27th. Finally, Wall Street Zen cut Ralliant from a “buy” rating to a “hold” rating in a research report on Sunday. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $69.00.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.